Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates.
about
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotypePhylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants.HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children.Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?Evolutionary dynamics of HIV-induced subversion of the immune response.Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usageUse of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitroThe growth and the control of human immunodeficiency virus in the lung: implications for highly active antiretroviral therapy.Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation.Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry.Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques.Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.Toll-like receptor 3 signalling up-regulates expression of the HIV co-receptor G-protein coupled receptor 15 on human CD4+ T cells.Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infectionC-C chemokines, pivotal in protection against HIV type 1 infection.A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject DrugsCCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120.The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells.CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transductionThe unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapyOral CCR5 inhibitors: will they make it through?Down-regulation of cell surface CXCR4 by HIV-1Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques.Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression.Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.Do beta-chemokines have clinical relevance in HIV infection?HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.Pathogenesis of HIV Infection.Host factors in the pathogenesis of HIV disease.Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne.Modeling of human CCR5 as target for HIV-I and virtual screening with marine therapeutic compounds.Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion.
P2860
Q28646874-5419A6DB-7462-4D13-9186-4A992E53C6DFQ30404569-7351C2D3-B551-45DA-8784-84F4E5A5C1E0Q33372329-AF9FD72B-91D6-4573-92FC-E6007B92F8A7Q33645423-4977A6D7-43B6-4F76-8ADF-FB8C51B4E89DQ33683341-5CC9A0D4-8964-4924-ACD3-846C541A298BQ33686847-65B8BDA7-67E1-4554-A479-97E93E4643DBQ33782007-B2F167FE-5EB2-481B-B8D9-EF9BCA8B6449Q33782296-4D6C270D-8ADF-439F-B861-2AE2027F0E9FQ33785490-70DC06BB-33B3-442F-A476-C6BA748937EDQ33785704-D8019442-706C-43F3-A53E-1DB8735195DBQ33785711-AC7A53B8-AA6D-49D3-9C41-FAEB482159BCQ33797534-A6A939FA-E53A-40A0-908E-DEA88D908F40Q33804258-1876D4B4-0DDF-4F39-9A39-65850E697295Q33813253-ADC94F1C-C963-44CD-8C0B-1DD1563EC7AAQ33941033-BA5A4F3D-41BC-4CFA-9262-01B341DB1F87Q33961448-2D122FE4-EC7D-4E27-8F92-A971875FC4F1Q34008699-2B1420A0-4DFE-465D-B5DE-B01E713EA1B9Q34757951-2C657FE5-CAE8-4549-BBCC-1F85E13B55A5Q34987062-B55F75A3-6696-4D27-A4EC-DB05774AF7C8Q35099526-BE09FE0B-6722-4C7A-92DF-F51063167635Q35140461-C1B702C9-EA42-49D1-9B45-1176F12FE500Q35576894-93612451-5E72-45EB-A40B-709595552730Q36011440-8B1153B0-7418-4867-BBE3-C298417C60F7Q36053084-B9839291-7093-40CE-8DE0-E31F521E84BFQ36097829-9B21D92B-D380-40FD-99ED-A21968C60052Q36264736-E3E24F8B-841D-472E-90BD-D3CE1C5B6ED5Q36324324-BF5914AC-73BF-450B-808E-3CBE787D7EB5Q36400457-074A755B-5FF1-435E-9628-08641588701AQ36458354-92B6AB82-5AAB-4D3E-ACCE-9CDEDD736D0DQ36470083-344C8A94-4977-4EE5-8805-1170F6BB110EQ36484034-AAB70234-2652-44F4-9B2A-A44EB1813355Q36580487-7C45862F-8B9B-40D8-B5F0-4A1C8D1EB993Q37356028-254BD7EA-B2DF-4B24-8B42-EBD6F66EE904Q37371340-82F3A2E1-26FE-4D08-982B-25B274DF2C70Q37444204-5E779686-FAEE-43D1-91B5-0960D0FF5B72Q38182590-D0F0303F-5C5C-40A7-B74D-CBDA8D50450AQ38949921-BDDB02F5-BD53-47ED-96F1-3D8463A9075DQ39137559-8BE5C9B0-74F5-4AE2-807B-6F8110296E30Q39210962-6CF85757-AA63-464A-B1D2-F37A95184048Q39355095-55A22EB3-CE29-4CC7-BA98-8A5729FB6F1A
P2860
Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sensitivity to inhibition by b ...... pes of primary HIV-1 isolates.
@en
Sensitivity to inhibition by b ...... pes of primary HIV-1 isolates.
@nl
type
label
Sensitivity to inhibition by b ...... pes of primary HIV-1 isolates.
@en
Sensitivity to inhibition by b ...... pes of primary HIV-1 isolates.
@nl
prefLabel
Sensitivity to inhibition by b ...... pes of primary HIV-1 isolates.
@en
Sensitivity to inhibition by b ...... pes of primary HIV-1 isolates.
@nl
P2093
P2860
P50
P356
P1476
Sensitivity to inhibition by b ...... pes of primary HIV-1 isolates.
@en
P2093
P2860
P304
15382-15387
P356
10.1073/PNAS.93.26.15382
P407
P577
1996-12-01T00:00:00Z